Lotus Biotech Development Corp.: 10-Q filed 2013-02-19

Name: Lotus Biotech Development Corp.: 10-Q filed 2013-02-19
Creator: Lotus Biotech Development Corp.

What Lotus Biotech Development Corp. reported in its quarterly report filed 2013-02-19 (fiscal Q3 2012): 11 published measures, 29 facts as tagged in accession 0001002014-13-000090.

This filing

Form: 10-Q (quarterly report)
Filed: 2013-02-19
Fiscal period: fiscal Q3 2012
Accession: 0001002014-13-000090 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Lotus Biotech Development Corp. filings.

Reported measures

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2012-12-31	14,869	USD
At 2012-03-31	-51,389	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2012-12-31	15,569	USD
At 2012-03-31	411	USD
At 2011-12-31	275	USD
At 2011-03-31	50	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2012-04-01 to 2012-12-31	-37,992	USD	275
2011-03-24 to 2012-12-31	-89,431	USD	649
2011-04-01 to 2011-12-31	-3,475	USD	275

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2012-04-01 to 2012-12-31	-48,708	USD	275
2011-03-24 to 2012-12-31	-68,297	USD	649
2011-04-01 to 2011-12-31	-3,825	USD	275

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2012-04-01 to 2012-12-31	63,866	USD	275
2011-03-24 to 2012-12-31	104,300	USD	649
2011-04-01 to 2011-12-31	4,050	USD	275

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2011-03-24 to 2012-12-31	-20,434	USD	649

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2012-12-31	15,569	USD
At 2012-03-31	411	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2012-12-31	700	USD
At 2012-03-31	51,800	USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2012-12-31	6,042,500	shares
At 2012-03-31	5,000,000	shares

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2012-10-01 to 2012-12-31	-25,758	USD	92
2012-04-01 to 2012-12-31	-37,992	USD	275
2011-03-24 to 2012-12-31	-89,431	USD	649
2011-07-01 to 2011-12-31	-200	USD	184
2011-04-01 to 2011-12-31	-3,475	USD	275

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2012-04-01 to 2012-12-31	59	USD	275
2011-03-24 to 2012-12-31	1,439	USD	649

Inspect the source

Entity: Lotus Biotech Development Corp. / CIK 0001520592
Captured: 2026-09-23 02:53 UTC
SEC response SHA-256: bb66e059f830b74605654323cb1a568c3bcc71a4f51b0be18e8739c2eaf2c9b9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001520592.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))